Ais Biotech (2023)
法国生物技术公司Ais Biotech近日宣布，其研发的新型抗流感分子在临床前研究中展现出显著潜力。该分子通过靶向流感病毒复制关键酶，旨在提供比现有疗法更广谱、更持久的保护效果。
公司创始人兼首席科学官表示，这一创新机制有望克服病毒耐药性问题，尤其对季节性流感和潜在的大流行毒株具有抑制作用。初步动物实验数据显示，该分子能有效降低病毒载量并缩短病程，且未观察到明显毒性反应。
目前，Ais Biotech已启动与多家国际制药公司的合作洽谈，计划于2024年提交临床试验申请。若研发顺利，该药物可能成为流感防治领域的重要补充，特别是在奥司他韦等传统药物疗效受限的背景下。
该项目获得了法国创新署及欧洲区域发展基金的部分资助，反映了欧盟对本土生物医药创新的支持。行业分析师指出，抗病毒药物市场持续增长，但针对流感的新型疗法仍存在未满足的临床需求，Ais Biotech的进展值得关注。
Ais Biotech, a French biotech company, has announced the development of a novel antiviral molecule, AIS-202, targeting influenza. The compound, derived from a proprietary library of synthetic molecules, is designed to inhibit the viral polymerase complex, a mechanism distinct from existing neuraminidase inhibitors like oseltamivir (Tamiflu).
Preclinical studies in animal models have demonstrated that AIS-202 significantly reduces viral load and lung inflammation. The company reports a 99% reduction in viral titers in treated mice compared to controls, with efficacy observed against multiple circulating strains, including H1N1 and H3N2.
CEO Dr. Sophie Laurent stated, "Our goal is to address the limitations of current therapies, particularly the emergence of resistant strains. AIS-202's novel target offers a promising path forward." The project has received €2.5 million in funding from Bpifrance and regional grants.
Ais Biotech plans to initiate Phase I clinical trials in early 2024, pending regulatory approval. If successful, the molecule could provide a new therapeutic option for seasonal and pandemic influenza, a global health priority.
Le développement d’une nouvelle molécule antigrippale
No companies linked yet